CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements
DOI:
https://doi.org/10.54097/hset.v8i.1110Keywords:
Chimeric Antigen Receptor T cell (CAR-T), Tumor Microenvironment (TME), Solid Tumor, Antigenic Specificity, Antigen Heterogeneity, Immunosuppressive State.Abstract
Chimeric antigen receptor T (CAR-T) cell immunotherapy shows potential and guarantee for clinical application in solid tumor treatment, although a section of difficulties must be overcome. Compared with conventional antitumor therapies, the advantages of CAR-T cell treatment include high specificity, great killing power, and long-term effectiveness. But various difficulties in treating solid tumors by CAR-T immunotherapy include intracellular signaling of CARs, immune escape due to antigenic heterogeneity of malignant tumors, physical or cytokine barriers that prevent CAR-T cell entry or limit their persistence, tumor microenvironment of other immunosuppressive molecules, and side effects. This paper describes CAR-T immunotherapy's mechanisms, development, and applications and discusses the status, difficulties, solutions, and future directions of treating solid tumors by CAR-T immunotherapy.
Downloads
References
Zhang ZZ, Wang T, Wang XF, Zhang YQ, Song SX, Ma CQ: Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies. Pharmacological research 2022, 175:106036.
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V et al: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science translational medicine 2015, 7(303):303ra139.
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z et al: Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 2022, 602(7897):503-509.
Newick K, O'Brien S, Moon E, Albelda SM: CAR T Cell Therapy for Solid Tumors. Annual review of medicine 2017, 68:139-152.
Srivastava S, Riddell SR: Engineering CAR-T cells: Design concepts. Trends in immunology 2015, 36(8):494-502.
Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pabón-Saldaña M, Darville L, Fang B, Rix U et al: An immunoproteomic approach to characterize the CAR interactome and signalosome. Science signaling 2019, 12(568).
Chmielewski M, Abken H: TRUCKs: the fourth generation of CARs. Expert opinion on biological therapy 2015, 15(8):1145-1154.
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A et al: Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Science translational medicine 2015, 7(275):275ra222.
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A et al: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science translational medicine 2017, 9(399).
Tumino N, Weber G, Besi F, Del Bufalo F, Bertaina V, Paci P, Quatrini L, Antonucci L, Sinibaldi M, Quintarelli C et al: Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma. Journal of hematology & oncology 2021, 14(1):191.
Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H et al: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature 2021, 599(7885):477-484.
Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S et al: Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer immunology research 2020, 8(3):309-320.
Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, Yang Q, Wang Y, Han W: Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein & cell 2018, 9(10):838-847.
Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM et al: Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology 2018, 155(1):29-32.
Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K et al: Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer cell 2019, 35(2):221-237.e228.
Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C et al: Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood 2020, 136(14):1632-1644.
Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT, Morris JS, Luong A, Martínez-Paniagua MA, Sanber K et al: CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia 2021, 35(1):75-89.
Feng Y, Liu X, Li X, Zhou Y, Song Z, Zhang J, Shi B, Wang J: Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. Oncoimmunology 2021, 10(1):1959102.
Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ et al: Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2015, 21(10):2278-2288.
Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G: Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer research 2014, 74(18):5195-5205.
Sun R, Luo H, Su J, Di S, Zhou M, Shi B, Sun Y, Du G, Zhang H, Jiang H et al: Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Molecular therapy : the journal of the American Society of Gene Therapy 2021, 29(1):60-74.
Spear P, Barber A, Rynda-Apple A, Sentman CL: Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. Journal of immunology (Baltimore, Md : 1950) 2012, 188(12):6389-6398.
Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, DeMatteo RP, Ayala A, Joseph Espat N, Junghans RP et al: Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer immunology, immunotherapy : CII 2015, 64(7):817-829.
Xia AL, Wang XC, Lu YJ, Lu XJ, Sun B: Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. Oncotarget 2017, 8(52):90521-90531.
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL et al: PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature medicine 2022.
Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JM, Palena C, Schlom J: Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. Journal for immunotherapy of cancer 2020, 8(1).
Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y et al: A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabolism 2022, 34(4):595-614.e514.
Jin C, Ma J, Ramachandran M, Yu D, Essand M: CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nature Biomedical Engineering 2022.
Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F: Improving CAR T-Cell Persistence. International journal of molecular sciences 2021, 22(19).
Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, Liu M, Zhou N, Lv J, Tang K et al: Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Science immunology 2020, 5(43).
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England journal of medicine 2014, 371(16):1507-1517.
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M: CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature medicine 2018, 24(6):731-738.
Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T et al: Senolytic CAR T cells reverse senescence-associated pathologies. Nature 2020, 583(7814):127-132.
Yang L, Yin J, Wu J, Qiao L, Zhao EM, Cai F, Ye H: Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol. Proceedings of the National Academy of Sciences of the United States of America 2021, 118(34).
Wu Y, Liu Y, Huang Z, Wang X, Jin Z, Li J, Limsakul P, Zhu L, Allen M, Pan Y et al: Control of the activity of CAR-T cells within tumours via focused ultrasound. Nature Biomedical Engineering 2021, 5(11):1336-1347.
Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE et al: Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature biotechnology 2020, 38(8):947-953.
Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK et al: CAR T cells produced in vivo to treat cardiac injury. Science (New York, NY) 2022, 375(6576):91-96.
Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, Li T, Shen Y, Fan X, Lin F et al: CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nature communications 2019, 10(1):4355.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
